TG Therapeutics, Inc. (TGTX)
54.17
+1.01
(+1.90%)
USD |
NASDAQ |
Oct 23, 16:00
54.35
+0.18
(+0.33%)
Pre-Market: 20:00
TG Therapeutics Price : 54.17 for Oct. 23, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | 52.56 | 55.80 | 51.83 | 54.17 | 1.978M |
| Oct 22, 2026 | 53.02 | 53.70 | 52.53 | 53.16 | 1.289M |
| Oct 21, 2026 | 54.51 | 54.95 | 52.73 | 53.20 | 1.178M |
| Oct 20, 2026 | 53.36 | 55.32 | 53.08 | 54.53 | 1.058M |
| Oct 19, 2026 | 54.35 | 54.97 | 52.90 | 53.30 | 1.550M |
| Oct 16, 2026 | 56.00 | 56.24 | 53.66 | 53.97 | 1.773M |
| Oct 15, 2026 | 55.12 | 56.83 | 54.76 | 56.00 | 1.809M |
| Oct 14, 2026 | 54.08 | 55.37 | 53.36 | 54.37 | 1.286M |
| Oct 13, 2026 | 55.23 | 55.39 | 53.63 | 54.34 | 1.001M |
| Oct 12, 2026 | 55.38 | 55.86 | 54.65 | 55.27 | 758152.0 |
| Oct 09, 2026 | 53.72 | 55.46 | 53.36 | 55.37 | 1.621M |
| Oct 08, 2026 | 53.34 | 53.90 | 52.12 | 53.34 | 1.735M |
| Oct 07, 2026 | 51.83 | 53.88 | 51.40 | 52.95 | 1.506M |
| Oct 06, 2026 | 54.11 | 54.11 | 51.34 | 52.19 | 2.412M |
| Oct 05, 2026 | 54.35 | 54.75 | 53.32 | 53.91 | 1.547M |
| Oct 02, 2026 | 54.17 | 54.98 | 53.14 | 54.29 | 1.650M |
| Oct 01, 2026 | 55.58 | 56.12 | 53.59 | 53.62 | 2.123M |
| Sep 30, 2026 | 56.41 | 56.98 | 55.36 | 55.78 | 1.908M |
| Sep 29, 2026 | 56.04 | 56.68 | 54.79 | 56.19 | 1.608M |
| Sep 28, 2026 | 57.35 | 57.66 | 55.88 | 56.19 | 1.442M |
| Sep 25, 2026 | 57.97 | 58.69 | 56.61 | 57.43 | 1.309M |
| Sep 24, 2026 | 55.95 | 57.55 | 55.09 | 57.52 | 1.138M |
| Sep 23, 2026 | 58.11 | 58.25 | 54.78 | 56.00 | 2.120M |
| Sep 22, 2026 | 57.41 | 58.62 | 56.56 | 58.11 | 2.085M |
| Sep 21, 2026 | 57.23 | 58.92 | 56.00 | 57.16 | 2.143M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Krystal Biotech, Inc. | 311.50 |
| Vertex Pharmaceuticals, Inc. | 523.93 |
| SELLAS Life Sciences Group, Inc. | 11.54 |
| Travere Therapeutics, Inc. | 50.08 |
| Alnylam Pharmaceuticals, Inc. | 224.03 |
Price Related Metrics
| PE Ratio | 19.73 |
| PS Ratio | 10.80 |
| PEG Ratio | 0.0311 |
| Price to Book Value | 13.73 |
| Price to Free Cash Flow | 496.76 |
| Earnings Yield | 5.07% |
| Market Cap | 8.292B |
| PEGY Ratio | 0.0311 |
| Operating PE Ratio | 63.35 |
| Normalized PE Ratio | 19.36 |